参考资料
- ^ Quittet P, Ceballos P, Lopez E, et al. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. Bone Marrow Transplant. 2006, 38 (4): 275–84 [2019-09-26]. PMC 2100150 . PMID 16883311. doi:10.1038/sj.bmt.1705441. (原始内容存档于2020-12-04).
- ^ Orozco H, Arch J, Medina-Franco H, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Archives of Surgery. 2006, 141 (2): 150–3; discussion 154. PMID 16490891. doi:10.1001/archsurg.141.2.150.
- ^ 醫療快訊:美國FDA批准抗腫瘤藥Dinutuximab上市.中國執業藥師.2015年.第6期:P24
- ^ 顧宏瓊.治療放化療所致白細胞減少症的藥物研究進展.中國藥業.2010年.第13期:P87-88